Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers

Overview of attention for article published in JAMA Neurology, December 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet
twitter: 16 X users

facebook: 1 Facebook page
reddit: 1 Redditor

Readers on

mendeley: 46 Mendeley

So far, Altmetric has seen 18 X posts from 16 X users, with an upper bound of 109,322 followers.

En el #DíaMundialdelaELA, recordamos la importancia de seguir investigando para encontrar soluciones para los pacientes que sufren esta enfermedad devastadora. #Investigación #Salud #Ciencia 🦠💊🔬 https://t.co/VM2jDVFi17

Recent ALS trials have employed stringent inclusion criteria to yield a homogeneous population of patients with rapidly progressing #ALS, which has improved trial efficiency. https://t.co/hY2qGf4x4m

Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers - JAMA Neurology Jour. via BrainSights for iOS https://t.co/NkBQmfU9st

Interesting paper. I have yet to really digest. It underplays NFL as a single Mode of action (MOA) marker. Its widely accepted that a treatment that smashes NFL is probably effective. The line about not being enough alone? I think I disagree for an iden…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 14 additional X posts.